Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

被引：0
|
作者：
Jeeyun Lee
Kyung Hae Jung
Young Suk Park
Joong Bae Ahn
Sang Jun Shin
Seock-Ah Im
Do Youn Oh
Dong Bok Shin
Tae Won Kim
Namsu Lee
Jae Ho Byun
Yong Sang Hong
Joon Oh Park
Se Hoon Park
Ho Yeong Lim
Won Ki Kang
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Research Institute and Hospital,Oncology, Department of Medicine, Samsung Medical Center
[3] Yonsei University College of Medicine,Center for Colorectal Cancer, National Cancer Center
[4] Seoul National University College of Medicine,Department of Internal Medicine
[5] Gachon University Gil Medical Center,Department of Internal Medicine
[6] University of Ulsan College of Medicine,Division of Hematology and Oncology, Department of Internal Medicine
[7] Soon Chun Hyang University Hospital,Division of Oncology, Department of Medicine, Asan Medical Center
[8] The Catholic University of Korea,Division of Hematology
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Statin; Simvastatin; Irinotecan; Cetuximab; Lovastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：657 / 663
页数：6
相关论文
共 50 条
  • [1] Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    Lee, Jeeyun
    Jung, Kyung Hae
    Park, Young Suk
    Ahn, Joong Bae
    Shin, Sang Jun
    Im, Seock-Ah
    Oh, Do Youn
    Shin, Dong Bok
    Kim, Tae Won
    Lee, Namsu
    Byun, Jae Ho
    Hong, Yong Sang
    Park, Joon Oh
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) : 657 - 663
  • [2] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer: Final results
    Kopetz, S.
    Glover, K.
    Eng, C.
    Wolff, R.
    Chang, D.
    Adinin, R.
    Morris, J.
    Abbruzzese, S.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [4] First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
    Claus-Henning Köhne
    Ralf Hofheinz
    Laurent Mineur
    Henry Letocha
    Richard Greil
    Josef Thaler
    Eva Fernebro
    Erick Gamelin
    Lucy DeCosta
    Meinolf Karthaus
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 65 - 72
  • [5] First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
    Koehne, Claus-Henning
    Hofheinz, Ralf
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Fernebro, Eva
    Gamelin, Erick
    DeCosta, Lucy
    Karthaus, Meinolf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (01) : 65 - 72
  • [6] 5-FLUOROURACIL, LEUCOVORIN AND IRINOTECAN (FOLFIRI) PLUS BEVACIZUMAB (BV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): A MULTICENTER PHASE II TRIAL
    Cordio, S.
    Parra, Soto H. J.
    Pumo, V
    Condorelli, S.
    Latteri, F.
    Sambataro, D.
    Rosati, G.
    Aprile, G.
    Fassari, G.
    De Pauli, F.
    Rimassa, L.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2009, 20
  • [7] Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study
    Lapeyre-Prost, A.
    Pernot, S.
    Sigrand, J.
    Mary, F.
    Le Malicot, K.
    Aparicio, T.
    Dahan, L.
    Caroli-Bosc, F-X.
    Lecomte, T.
    Doat, S. Racine
    Marthey, L.
    Desrame, J.
    Lepage, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 160 - 160
  • [8] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Ting Deng
    Le Zhang
    Xiao-jian Liu
    Jian-ming Xu
    Yu-xian Bai
    Yan Wang
    Yu Han
    Yu-hong Li
    Yi Ba
    Medical Oncology, 2013, 30
  • [9] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Deng, Ting
    Zhang, Le
    Liu, Xiao-jian
    Xu, Jian-ming
    Bai, Yu-xian
    Wang, Yan
    Han, Yu
    Li, Yu-hong
    Ba, Yi
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [10] A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer
    Van Cutsem, E
    Pozzo, C
    Starkhammar, H
    Dirix, L
    Terzoli, E
    Cognetti, E
    Humblet, Y
    Garufi, C
    Filez, L
    Gruia, G
    Cote, C
    Barone, C
    ANNALS OF ONCOLOGY, 1998, 9 (11) : 1199 - 1204
12345